San Diego, California–(Newsfile Corp. – November 2, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“ Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug (“IND“) application to the U.S. Food and Drug Administration (“FDA“) to evaluate its…
